Responsible use

Nicotine is addictive. Pouches are substantially less harmful than smoking, but they are not harmless. We sell them; we don't market them as healthy.

What the harm-reduction position says

The UK government's position (and that of Public Health England's successor agencies) is that nicotine-only delivery products — pouches, gums, lozenges — carry a small fraction of the long-term health risk of combustible tobacco. The Swedish epidemiological record on tobacco snus, the closest long-running cohort, supports a similar conclusion: substantially reduced risk of smoking-related disease compared to cigarettes.

That is not a clean bill of health. Nicotine itself is addictive, raises blood pressure transiently, and has documented developmental risks for adolescents. The medical literature on long-term oral pouch use is younger than the products are popular — caveats apply.

What we don't know yet

  • Long-term gum and oral-tissue effects (cohort data is <15 years).
  • Cardiovascular impact of sustained 20–40 mg/day nicotine delivery via pouches specifically (most data is from cigarette and gum users).
  • Interactions with high-strength (≥20 mg/g) and Hyper-Strong products that have entered the market since 2022.
  • Use patterns in non-smoking-quit-pathway users (younger first-time nicotine users).

We surface what we know. We don't pretend to know what we don't.

If you're using pouches to quit smoking

You're using them as intended. The harm-reduction case is strongest for current or recent smokers switching to a non-combustible source. Pick a strength that satisfies your craving (cigarettes deliver roughly 1–1.5 mg of nicotine each — match that with pouch strength × pouch count). Cycle down gradually if your eventual goal is full cessation.

If you want to stop using nicotine entirely

The typical taper path: drop one strength tier every 2–4 weeks (e.g. 11 mg/g → 6 mg/g → 3 mg/g → off). Pouch-count reduction works in parallel. Most users find pouches easier to taper than cigarettes because you control dose precisely.

Country-specific cessation support:

  • UK: NHS Smokefree — nhs.uk/better-health/quit-smoking
  • Sweden: Sluta-röka-linjen — 020 84 00 00
  • Norway: Slutta-app and helsenorge.no
  • Germany: Bundeszentrale für gesundheitliche Aufklärung — rauchfrei-info.de
  • US: 1-800-QUIT-NOW or smokefree.gov
  • Other markets: local primary-care provider or pharmacist.

Special cases

  • Pregnancy: Do not use nicotine pouches. The medical consensus is that any nicotine exposure during pregnancy carries fetal developmental risk.
  • Cardiovascular conditions: Consult your cardiologist before regular use. Acute nicotine raises blood pressure and heart rate transiently.
  • Adolescents: Do not use. We do not sell to anyone under the legal age in their jurisdiction (18+ most markets, 21+ in the United States).
  • Concurrent NRT: If you're using prescription nicotine-replacement therapy alongside pouches, your total nicotine dose may exceed therapeutic intent. Talk to your prescriber.